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Abstract 
Background: Myocardial fibrosis occurs in end-stage heart failure secondary to mitral regurgitation (MR), but it is not 
known whether this is present before onset of symptoms or myocardial dysfunction. This study aimed to characterise 
myocardial fibrosis in chronic severe primary MR on histology, compare this to tissue characterisation on cardiovascu-
lar magnetic resonance (CMR) imaging, and investigate associations with symptoms, left ventricular (LV) function, and 
exercise capacity.
Methods: Patients with class I or IIa indications for surgery underwent CMR and cardiopulmonary exercise testing. LV 
biopsies were taken at surgery and the extent of fibrosis was quantified on histology using collagen volume fraction 
 (CVFmean) compared to autopsy controls without cardiac pathology.
Results: 120 consecutive patients (64 ± 13 years; 71% male) were recruited; 105 patients underwent MV repair 
while 15 chose conservative management. LV biopsies were obtained in 86 patients (234 biopsy samples in total). 
MR patients had more fibrosis compared to 8 autopsy controls (median: 14.6% [interquartile range 7.4–20.3] vs. 3.3% 
[2.6–6.1], P < 0.001); this difference persisted in the asymptomatic patients  (CVFmean 13.6% [6.3–18.8], P < 0.001), but 
severity of fibrosis was not significantly higher in NYHA II-III symptomatic MR  (CVFmean 15.7% [9.9–23.1] (P = 0.083). 
Fibrosis was patchy across biopsy sites (intraclass correlation 0.23, 95% CI 0.08–0.39, P = 0.001). No significant rela-
tionships were identified between  CVFmean and CMR tissue characterisation [native T1, extracellular volume (ECV) 
or late gadolinium enhancement] or measures of LV function [LV ejection fraction (LVEF), global longitudinal strain 
(GLS)]. Although the range of ECV was small (27.3 ± 3.2%), ECV correlated with multiple measures of LV function (LVEF: 
Rho = − 0.22, P = 0.029, GLS: Rho = 0.29, P = 0.003), as well as NTproBNP (Rho = 0.54, P < 0.001) and exercise capacity 
(%PredVO2max: R = − 0.22, P = 0.030).
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Introduction
Chronic primary mitral regurgitation (MR) exposes the 
left ventricle (LV) to a volume overload, with progressive 
remodelling, left ventricular (LV) dilatation, and myocar-
dial dysfunction. Despite long-standing guidelines on the 
indications for surgery in symptomatic and asymptomatic 
severe chronic primary MR, one fifth of patients con-
tinue to present post-operatively with reduced LV  ejec-
tion fraction (LVEF) and an increased risk of later heart 
failure [1]. Although there is support for early repair in 
asymptomatic patients at low risk of complications, there 
are limited randomised data to separate early repair from 
watchful waiting. Given the ageing of the population, the 
proportion of older patients with asymptomatic severe 
chronic primary MR is growing and these patients do not 
always find the option even of low risk surgery attrac-
tive in the absence of symptomatic benefit. Current class 
I indications for surgery in asymptomatic individuals 
require confirmation of severe MR, LV cavity dilatation 
(end systolic dimension ≥ 4.0  cm) and LVEF ≤ 60%, yet 
intervention based on these cut-offs is associated with a 
50% reduction in long-term survival and 2.5 fold increase 
in risk of heart failure [2]. Given the limitations of these 
parameters in the management of primary MR, there is a 
need for additional information to support either watch-
ful waiting or early surgery [3].
Early autopsy studies in patients with chronic severe 
primary MR demonstrated a stepwise increase in myo-
cardial fibre hypertrophy and interstitial space with 
increasing symptoms and LV dysfunction [4]. However, 
these changes were only found to be significant in those 
who died with advanced heart failure; meanwhile, animal 
studies have suggested that progressive development of 
supra-normal levels of myocardial fibrosis with exhaus-
tion of muscle hypertrophy mechanisms is responsible 
for the onset of heart failure in MR [5]. While histological 
data in humans are limited, there has been rapid growth 
in studies using cardiovascular magnetic resonance 
(CMR) imaging to characterise LV remodelling and myo-
cardial architecture in primary MR. Late gadolinium 
enhancement (LGE) has been identified in a significant 
proportion of patients with chronic severe primary MR 
before surgery and is thought to reflect focal replace-
ment fibrosis [6, 7]. In previous studies, we and others 
have demonstrated elevated myocardial T1 relaxation 
times and expansion of the extracellular volume frac-
tion (ECV), an imaging biomarker of diffuse interstitial 
fibrosis (DIF), in asymptomatic primary MR [6, 8]. How-
ever, histological data in asymptomatic primary MR are 
lacking, and there are no data linking fibrosis on histol-
ogy with either T1, ECV, LGE or functional change in 
the LV. Our hypothesis is that volume overload in severe 
MR is associated with fibrosis that can be measured by 
CMR tissue characterisation, and that fibrosis is associ-
ated with symptom status, impaired global longitudinal 
strain and reduced exercise capacity. Therefore, the aims 
of this prospective study of patients with chronic severe 
primary MR were to assess: (i) the histological changes 
within the myocardium; (ii) the association between his-
tological extent of fibrosis and tissue characterisation on 
CMR; (iii) the relationship between extent of myocardial 




All patients were enrolled in the prospective multicentre 
Mitral FINDER study from three tertiary cardiothoracic 
centres with high volume mitral valve repair programmes 
(patients undergoing surgery at: Queen Elizabeth Hospi-
tal Birmingham n = 52, Coventry Hospital n = 49, New 
Cross Hospital n = 3; clinicaltrials.gov NCT02355418) 
between August 2015 and March 2018. Full study inclu-
sion and exclusion criteria have been reported [9], with 
patients referred for mitral valve surgery based on Euro-
pean Society of Cardiology class I or class IIa indica-
tions [10]. In brief, consecutive adult patients aged over 
18 years were included, based on the presence of severe 
primary degenerative MR, diagnosed and quantified on 
echocardiography according to standard guidelines [11]. 
Patients were excluded if they had primary MR not due 
to degenerative disease, secondary MR, congenital heart 
disease, inherited or acquired cardiomyopathy, a his-
tory of myocardial infarction, symptomatic concomitant 
coronary artery disease, moderate or severe aortic valve 
disease, pregnancy, or could not undergo either CMR or 
cardiopulmonary exercise testing (CPET).
Conclusions: Patients with chronic primary MR have increased fibrosis before the onset of symptoms. Due to the 
patchy nature of fibrosis, CMR derived ECV may be a better marker of global myocardial status.
Clinical trial registration Mitral FINDER study; Clinical Trials NCT02355418, Registered 4 February 2015, https ://clini caltr 
ials.gov/ct2/show/NCT02 35541 8
Keywords: Mitral regurgitation, Histological fibrosis, Extracellular volume, Late gadolinium enhancement, Myocardial 
strain, Exercise capacity, Symptom status
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All patients underwent clinical assessment with history 
and examination, blood sampling [including full blood 
count, haematocrit, renal function, N-terminal pro-brain 
natriuretic peptide (NTproBNP)], symptom assessment 
with New York Heart Association (NYHA) classifica-
tion and multiparametric CMR at the primary study site 
(Queen Elizabeth Hospital Birmingham).
Classification into fibroelastic deficiency (FED) ver-
sus Barlow’s disease was based on independent review 
of echocardiographic and CMR imaging by two experi-
enced imaging cardiologists (RPS, NCE), and confirmed 
on surgery.
The study received favourable ethical review from the 
UK National Research Ethics Service (15/EM/0243) and 
conformed to the Helsinki Declaration. Subjects gave 
written consent to participate.
Histology
During mitral valve  surgery, three LV biopsies were 
obtained from each patient from the LV septum, ante-
rior and posterior free wall, using a 14G TruCut needle 
or scalpel. Histological analyses were performed blinded 
to clinical and imaging data (DN, BL). Myocardial con-
nective tissue was analysed on ×20 scanned Masson 
Trichrome sections (Axio Scan.Z1 ZEISS, Oberkochen, 
Germany) which stains extracellular connective tissue 
blue and stains muscle purple-red. Fibrosis burden quan-
tified as collagen volume fraction (CVF) was derived 
from Ilastik machine-learning based, supervised object 
classification and segmentation software [12], which was 
trained in-house against an expert (DN). This system 
identified and quantified the surface area of connective 
tissue versus the surface area of muscle.  CVFmean rep-
resents the mean average of CVF values from the three 
biopsies originating from an individual patient, and 
 CVFmax represents the highest CVF across the three 
sites for the individual patient, or from all available sites 
in those where it was not possible to collect all three 
biopsies.
Control myocardial samples from single whole-
heart autopsy sections were obtained from autopsies 
of eight subjects (five males, all Caucasian, mean age 
59 ± 6.9  years). These data allowed comparison of age-
related histological changes in subjects who died of 
non-cardiac causes with no evidence of macroscopic or 
microscopic cardiac lesions.
Measurement of cardiomyocyte hypertrophy was per-
formed by manually quantifying the cross-sectional area 
(CSA) of 50 randomly selected cardiomyocytes via ZEN 
software (Carl Zeiss Microscopy). To ensure consistency, 
only cardiomyocytes found in its mid-axial orientation 
(denoted by presence of central nuclei) were eligible for 
quantification.
Cardiovascular magnetic resonance
LV and right ventricular (RV) volumes and mass, and 
left atrial volumes were acquired in line with 1.5T CMR 
scanner (Avanto; Siemens Healthineers, Erlangen, Ger-
many) protocols [13, 14]. Single breath hold modified 
Look-Locker inversion recovery sequence (MOLLI) was 
used for T1 mapping in the LV base and mid-ventricular 
short axis levels before and between 15 and 20 min after 
contrast administration (3, 3, 5 scheme), according to 
previously published parameters [8]. LGE imaging was 
performed 7 to 10 min after 0.15 mmol/kg of gadolinium 
based-contrast agent (Gadovist Bayer Healthcare, Berlin, 
Germany).
CMR imaging analyses were performed offline using 
 Cvi42® (version 5.3.6, Circle Cardiovascular Imag-
ing, Calgary, Canada) by an operator (BL) blinded to all 
demographic and descriptive data, and without informa-
tion regarding any clinical parameters. For ventricular 
volume analysis, the endocardial border was detected 
with thresholding, delineation of atria/ventricles was 
confirmed in matched long axis planes, and papillary 
muscles and trabeculations were included in ventricular 
mass. For T1 mapping, two short axis maps (base and 
mid LV) were manually contoured for endo- and epicar-
dial borders. Partial voluming of blood was minimised by 
using a 20% offset from the endo- and epicardial border 
[15]. ECV values stated in the manuscript are global val-
ues. Blood was taken for measurement of haematocrit at 
the same time as the CMR scans. Additional region-of-
interest (ROI) ECV values were obtained from the mid 
LV septum, anterior free wall and posterior free wall, to 
mirror the origins of histological biopsy collection. Myo-
cardial deformation on CMR was quantified using feature 
tracking of cine images with  Cvi42®, as per previously 
described methodology [16, 17]. LGE mass was quanti-
fied automatically using a signal intensity thresholding of 
> 3 standard deviations above reference mean [18].
Symptom status and exercise testing
Symptom status was assessed using the NYHA classifica-
tion status, as assessed by the responsible clinician, with 
NYHA I classified as asymptomatic and NYHA II–IV as 
symptomatic. Objective testing of exercise capacity was 
carried out using maximal exertion treadmill CPET, with 
incremental ramp protocols as per American Thoracic 
Society guidelines [19].
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Statistical analyses
The baseline demographics of the cohort were sum-
marized, with continuous variables reported as 
means ± standard deviations (SDs) where normally 
distributed, and as medians and interquartile ranges 
(IQRs) otherwise. Comparisons of continuous vari-
ables between groups were performed using independ-
ent samples t-tests for normally distributed variables, or 
Mann–Whitney U tests otherwise, with  chi2-tests used 
to analyze nominal variables. Associations between con-
tinuous variables were assessed using Spearman’s (rho) or 
Pearson’s (R) correlation coefficients. Where applicable, 
these associations were further quantified using linear 
regression models. The goodness of fit of these regres-
sion models was assessed graphically, with logarithmic 
transformations applied where either poor fit or hetero-
scedasticity were identified. All statistical analyses were 
performed using SPSS (version 24, Statistical Package 
for the Social Sciences, International Business Machines, 
Inc., Armonk, New York, USA), and P < 0.05 was deemed 
to be statistically significant throughout.
Results
In total, 120 consecutive patients with severe primary 
degenerative MR were recruited, of whom 105 were 
referred for mitral valve repair. One patient referred for 
surgery was subsequently excluded due to a require-
ment for percutaneous coronary intervention, leav-
ing n = 104 for analysis, of whom 39 were referred for a 
class I indication (symptoms) and 65 were referred for a 
class IIa indication (high likelihood of repair). Only one 
patient required MV replacement. As expected given the 
indications for surgery, most of the cohort were asymp-
tomatic, with 63% (n = 65) New York Heart Association 
(NYHA) class 1, 30% (n = 31) NYHA class II, and 8% 
(n = 8) NYHA class III. Demographic, histology and 
imaging data are summarised in Table 1. All 15 patients 
that declined surgery were asymptomatic with a class IIa 
indication for repair, but chose to be treated conserva-
tively. Patients choosing conservative management were 
significantly older with lower estimated glomerular filtra-
tion rate (eGFR), but had smaller LV end-systolic volume 
index (LVESVI) and less MR (Additional file 1: Table S1).
Histology of myocardial biopsies in severe chronic primary 
MR
Of the 104 patients undergoing MV repair, 234 biop-
sies were collected from 86 patients. Biopsies were 
taken from all three LV sites (septum, anterior and pos-
terior free wall) in n = 67, with n = 14 having two biop-
sies, and n = 5 a single biopsy. Biopsies were not feasible 
across all biopsy sites due to limited visualisation or safe 
instrument access to the ventricular myocardium from 
the left atrial incision at the time of surgery. In addition, 
two patients chose to undergo surgery at institutions 
external to the study sites, where biopsies were not taken.
Myocardial fibrosis
MR patients had a median  CVFmean of 14.6% [IQR 
7.4–20.3] and  CVFmax of 22.2% [10.2–31.8], which 
were significantly higher than control CVF values (3.3% 
[2.6–6.1], P < 0.001). The difference in fibrosis persisted 
when limited to asymptomatic MR patients compared 
to controls  (CVFmean 13.6% [6.3–18.8], P < 0.001). 
Although there was a trend towards increased fibrosis 
in symptomatic patients compared to asymptomatic 
MR patients based on NYHA classification, this was 
not significant  (CVFmean 15.7% [9.9–23.1] (P = 0.083) 
(Fig.  1; results remain non-significant when taking 
biopsy location and exclusion/inclusion of endocar-
dium into account, Additional file  1: Table  S3). There 
were no gender-related differences in fibrosis  (CVFmean 
male 14.1% [7.3–18.5] vs. female 16.1% [11.4–24.6], 
P = 0.163).
A total of 124 myocardial biopsies contained endo-
cardium (median thickness 100 µm [58–181]), and 111 
biospies contained only myocardium. Biopsies with 
endocardium showed higher CVF than those without 
endocardium (16.7% [10.4–27.1] vs. 6.6% [3.5–12.3], 
P < 0.001). There was a significant correlation between 
mean endocardial thickness and CVF (rho = 0.35, 
P < 0.001), consistent with endocardial thickening 
and subendocardial scar. The pattern of fibrosis var-
ied between MR patients and within the myocardium, 
including diffuse interstitial fibrosis, perivascular fibro-
sis and areas of replacement fibrosis (Fig. 2).
There was no clear pattern to the distribution of 
myocardial fibrosis within each individual biopsy sam-
ple; although CVF in samples with endocardium was 
approximately twice that of mid-myocardial samples, 
no clear endocardial–epicardial gradient could be seen 
within the myocardium of each biopsy sample. In the 
67 patients who had three biopsies, this heterogene-
ity was reflected in a low intraclass correlation coef-
ficient (ICC) for fibrosis across the three biopsy sites 
(ICC = 0.23, 95% CI 0.08–0.39, P = 0.001).
Cellular hypertrophy
Direct histological quantification of cardiomyocyte 
hypertrophy was performed via haematoxylin and 
eosin (H&E) stained slides. MR patients were found 
to possess marked cardiomyocyte hypertrophy com-
pared to controls (CSA 853 ± 230 µm2 vs 124 ± 26 µm2, 
P < 0.001, Fig.  1) with histological quantification 
Page 5 of 12Liu et al. J Cardiovasc Magn Reson           (2020) 22:86  
correlating significantly with CMR derived LV mass 
indexed (LVMI; R = 0.36, P = 0.001). There was a trend 
for cardiomyocyte CSA in symptomatic patients to be 
lower than asymptomatic patients (799 ± 218  µm2 vs 
891 ± 232 µm2, P = 0.069).
Table 1 Baseline characteristics of surgical patients according to symptom status
Data are reported as N (%), with P-values from  chi2 tests; median (interquartile range), with P-values from Mann–Whitney U tests; or as mean ± SD, with P-values from 
independent samples t-tests, as applicable. Italic P-values are significant at P < 0.05
%PredVO2max percentage predicted maximal oxygen consumption, BMI body mass index, ECV extracellular volume, eGFR estimated glomerular filtration rate, GCS 
global circumferential strain, GLS global longitudinal strain, LGE late gadolinium enhancement, LAVI left atrial volume indexed, LVEDVI left ventricular diastolic volume 
indexed, LVEF left ventricular ejection fraction, LVESD left ventricular end-systolic dimension, LVESVI left ventricular systolic volume indexed, LVMI left ventricular mass 
indexed, MLHFQ Minnesota living with heart failure questionnaire, MR mitral regurgitation, RVEF right ventricular ejection fraction, RV Ell right ventricular longitudinal 







 Age (years) 104 62 ± 14 64 ± 12 0.428
 Male sex 104 50 (77%) 26 (67%) 0.254
 BMI (kg/m2) 104 25 ± 4 27 ± 5 0.065
 BSA  (m2) 104 1.88 ± 0.23 1.91 ± 0.23 0.491
 Treated hypertension 104 20 (31%) 12 (31%) 1.000
Atrial fibrillation 104 0.008
 None 53 (82%) 21 (54%)
 Paroxysmal 2 (3%) 5 (13%)
 Permanent 10 (15%) 13 (33%)
eGFR (ml/min/1.73m2) 104 75 (65–84) 72 (60–82) 0.401
Degeneration subtype 104 0.076
 Barlow’s disease 24 (37%) 11 (28%)
 Indeterminant 3 (5%) 7 (18%)
 Fibroelastic deficiency 38 (58%) 21 (54%)
MLHFQ score 103 5 (1–17) 43 (30–57) < 0.001
%PredVO2max (%) 103 99 ± 20 79 ± 22 < 0.001
Resting PASP (mmHg) 85 33 ± 10 38 ± 20 0.071
Ventricular ectopy burden (%) 54 0.1 (0.0–1.0) 0.5 (0.0–1.4) 0.356
Cardiac magnetic resonance characteristics
 LVEDVI (ml/m2) 104 105 ± 22 103 ± 21 0.663
 LVESVI (ml/m2) 104 33 ± 13 35 ± 11 0.342
 LVESD (mm) 104 3.7 ± 0.7 3.8 ± 0.6 0.380
 LVMI (g/m2) 104 71 ± 13 66 ± 13 0.045
 LVEF (%) 104 70 ± 8 66 ± 9 0.065
 GCS (%) 102 − 18.2 ± 3.0 − 16.6 ± 3.5 0.017
 GLS (%) 102 − 15.9 ± 2.7 − 14.8 ± 3.3 0.099
 LAVI (ml/m2) 102 88 ± 44 96 ± 47 0.341
 RVESVI (ml/m2) 104 31 ± 9 33 ± 13 0.474
 RVEF (%) 104 57 ± 8 55 ± 10 0.122
 RV  Ell 104 − 21.6 ± 4.5 − 21.4 ± 5.0 0.811
 MR volume (ml) 104 62 ± 27 67 ± 36 0.410
 MR fraction (%) 104 44 ± 12 49 ± 19 0.121
 ECV (%) 101 26.8 ± 3.1 28.2 ± 3.3 0.045
 Native T1 (ms) 103 981 ± 24 991 ± 26 0.054
 LGE presence (n, %) 102 22 (34%) 12 (32%) 0.830
 LGE quantification (g) 102 0.00 (0.00–0.37) 0.00 (0.00–0.24) 0.452
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Fatty infiltration
During examination of surgical biopsies, fat infiltra-
tion between cardiomyocytes was noted. As a potential 
confounder to T1 and ECV measurements (T2 mapping 
was not performed), fat infiltration was semi-quantita-
tively assessed by an experienced cardiac histopatholo-
gist blinded to clinical and imaging data using a scale of 0 
(no fat infiltration) to 3 (prominent fat infiltration). Of 79 
biopsies assessed, 52 (66%) contained no fat infiltration, 
15 (19%) mild; 10 (13%) moderate; and 2 (3%) promi-
nent fat infiltration (Fig. 2). Although extent of fat infil-
tration increased significantly with  CVFmean (rho = 0.23, 
P = 0.045), there were no signficiant correlations with 
CMR parameters, including native T1 or ECV. There 
was however, a near-significant correlation with age 
(rho = 0.22, P = 0.056).
Histology and CMR measurement of myocardial fibrosis
The extent of histological fibrosis quantified on biopsy by 
 CVFmean did not correlate significantly with either with 
native T1 (rho = 0.04, P = 0.714), or ECV (rho = 0.18, 
P = 0.101) regardless of whether analyses were performed 
according to global values (Fig. 3a) or according to region 
of interest drawn to match biopsy site (Additional file 2: 
Figure S1). However, a statistically significant association 
between  CVFmean and ECV was present when eliminating 
endocardium from any analysis and limiting histological 
quantification to myocardium only (n = 56, rho = 0.33, 
P = 0.015; Fig.  3b). Conversely, no association was pre-
sent between ECV and  CVFmean quantified from biopsies 
containing endocardium (n = 64, rho = 0.03, P = 0.822).
LGE was present in 34 (33%) of 102 patients who 
received gadolinium-based contrast agent, with a median 
mass of 0.98 g (IQR 0.33–2.47). Mid-myocardial LGE was 
located in the basal inferolateral LV segment (n = 23), 
and/or in the papillary muscles (n = 8), basal anterolat-
eral segment (n = 3), mid inferolateral segment (n = 2) 
and mid septum (n = 1). The extent of histological fibro-
sis quantified on biopsy by  CVFmean was not signifi-
cantly correlated with the amount of left ventricular LGE 
(rho = − 0.09, P = 0.402).
Myocardial fibrosis, LV function and exercise capacity
The extent of histological fibrosis quantified on biopsy 
by  CVFmean was not significantly correlated with CMR 
measured LV volumes, LVEF or LV mass, and there 
was no relationship with other imaging markers of LV 
function, including GLS and E/eʹ. There was however, 
a signficant positive correlation between  CVFmean and 
NTproBNP (Rho = 0.35, P = 0.001) (Table 2). Sub-analy-
sis using  CVFmean derived from biopsy samples without 
endocardium did not result in any alterations in statisti-
cal significance (data not shown). There was a consist-
ent and significant correlation however, between ECV 
and multiple parameters of LV function (LVEF, LVESVI, 
global longitudinal strain (GLS) and E/eʹ), as well as 
Fig. 1 Boxplots illustrating the distribution of mean collagen 
volume fraction  (CVFmean) (top) and cardiomyocyte cross sectional 
area (CSA) (bottom) in autopsy controls vs. asymptomatic and 
symptomatic mitral regurgitation (MR) patients. P values are derived 
from Mann–Whitney U tests for non-parametric variables (collagen 
volume fraction) and independent T-test for parametric variables 
(cardiomyocyte cross sectional area, extracellular volume). MR mitral 
regurgitation
Page 7 of 12Liu et al. J Cardiovasc Magn Reson           (2020) 22:86  
Fig. 2 Histological specimens from mitral regurgitation patients and controls. Sections are stained with Masson Trichrome highlighting fibrous 
tissue as blue and myocytes as purple-red. Histological fibrosis is patchy with little congruence in fibrosis burden across different biopsy sites. 
Extracellular volume fraction (ECV) can provide an overall estimation of myocardial status, but fails to account for endocardial fibrosis
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NTproBNP. The amount of LGE in the cohort was small 
and there was no significant difference in CMR measured 
LVEF, LVESVI or GLS, E/eʹ or NTproBNP between 
patients with or without LGE.
Fig. 3 Relationship between ECV and histological evidence of interstitial fibrosis on biopsy (CVFmean) for a all biopsies, and b biopsies containing 
only myocardium. The trendlines are based on regression models, with ECV as the independent variable, and  Log2CVFmean as the independent 
variable. This relationship was not found to be statistically significant when all biopsies were included within analyses (a, Rho = 0.18, P = 0.101, 
N = 83), but became statistically significant when limiting analyses to biopsies that contained only myocardium (b, Rho = 0.33, P = 0.015, N = 56)
Table 2 Correlation of histological fibrosis against non-invasive pre-operative imaging parameters
Results are from Spearman’s (Rho) correlation coefficients. Italic P-values are significant at P < 0.05
ECV extracellular volume, GCS global circumferential strain, GLS global longitudinal strain, LAVI left atrial volume indexed, LGE late gadolinium enhancement, LVEDVI 
left ventricular diastolic volume indexed, LVEF left ventricular ejection fraction, LVESVI left ventricular systolic volume indexed, LVMI left ventricular mass indexed, MR 
mitral regurgitation, NTproBNP N-terminal pro-brain natriuretic peptide, PASP pulmonary artery systolic pressure, RVEF right ventricular ejection fraction, RV Ell right 
ventricular longitudinal strain, RVESVI right ventricular end-systolic volume indexed
a Dichotomous variables
b GCS and GLS are expressed as negative values, therefore a positive correlation between ECV and strain suggests that increased ECV is related with worse (less 
negative) strain
Correlation with  CVFmean Correlation with ECV
N Rho P-value N Rho P-value
LVEDVI (ml/m2) 86 − 0.02 0.853 101 0.12 0.234
LVESVI (ml/m2) 86 0.07 0.541 101 0.22 0.025
LVMI (g/m2) 86 − 0.12 0.261 101 − 0.05 0.640
LVEF (%) 86 − 0.15 0.178 101 − 0.22 0.029
GCS (%)b 84 0.14 0.221 99 0.31 0.002
GLS (%)b 84 0.12 0.271 99 0.29 0.003
LAVI (ml/m2) 84 0.17 0.123 99 0.26 0.008
Echocardiography E/eʹ 72 0.09 0.460 87 0.25 0.022
NTproBNP 84 0.35 0.001 99 0.54 < 0.001
RVESVI (ml/m2) 86 − 0.10 0.381 101 0.21 0.037
RVEF (%) 86 − 0.06 0.579 101 − 0.14 0.170
RV  Ell 86 0.09 0.411 101 0.30 0.003
MR volume (ml) 86 0.04 0.714 101 − 0.07 0.471
MR fraction (%) 86 0.16 0.147 101 0.02 0.868
ECV (%) 83 0.18 0.101 – – –
Native T1 (ms) 85 0.04 0.714 101 0.62 < 0.001
LGE  presencea 84 − 0.07 0.514 101 0.06 0.535
PASP (mmHg) 71 0.14 0.232 82 0.14 0.209
Degeneration subtype (Barlow’s)a 77 0.21 0.070 91 0.13 0.208
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Four patients undergoing surgery were unable to 
complete cardiorespiratory symptom-limited CPET 
due to non-cardiorespiratory causes (severe osteoar-
thritis and anxiety). Mean peak oxygen consumption 
 (VO2) was 23.2 ± 7.4 ml/kg/min, giving a %PredVO2max 
of 92.9 ± 20.5%, at an age-predicted heart rate of 
99.0 ± 14.8%. On linear regression, formally tested exer-
cise capacity quantified as %PredVO2 max  was signifi-
cantly associated with ECV, markers of biventricular 
systolic function, E/eʹ, the presence of atrial fibrillation, 
and pulmonary artery systolic pressure, but not with 
 CVFmean (Table 3).
Impact of MR subtype
Sub-group analysis of patients with BD demonstrated 
higher  CVFmax compared to FED patients (median 28.0% 
[IQR 16.7–42.8] vs. 20.2% [7.5–29.4], P = 0.009), but 
not  CVFmean (15.4% [12.1–25.3] vs. 14.0% [5.5–19.1], 
P = 0.071). There were no significant differences in biven-
tricular volumes, LVEF, LVMI or MR severity; ECV and 
LGE prevalence were also similar (Additional file  1: 
Table S2).
Discussion
This is the most comprehensive study to characterise 
myocardial changes in patients with chronic primary 
severe MR, combining CMR based assessment of struc-
tural changes with detailed invasive histological profiling, 
and the identification of functional correlates.
Our work provides definitive histological evidence for 
the presence of myocardial fibrosis, even in asympto-
matic MR patients with normal range CMR volumetric 
parameters and good exercise capacity. We noted com-
plex morphology and topography of fibrosis with three 
Table 3 Linear regression analyses of exercise capacity against histology, cardiac imaging and pulmonary pressures
Results are from Pearson’s (R) correlation coefficients and univariable regression models with %PredVO2max as the dependent variable. Italic P-values are significant at 
P < 0.05
AF atrial fibrillation, BMI body mass index, CSA cross-sectional area, CVF collagen volume fraction, ECV extracellular volume, GCS global circumferential strain, GLS 
global longitudinal strain, LGE late gadolinium enhancement, LVEF left ventricular ejection fraction, LVESVI left ventricular systolic volume indexed, LVMI left ventricular 
mass indexed, MR mitral regurgitation, RVEF right ventricular ejection fraction, RV Ell right ventricular longitudinal strain, RVESVI right ventricular end-systolic volume 
indexed, PASP pulmonary artery systolic pressure
a Factors were  log2-transformed to improve model fit, hence coefficients are relative to a two-fold increase in the factor
b Factors are dichotomous; hence the coefficient represents the difference in the outcome between the stated category and the reference category
Relationship with %PredVO2max
N R Coefficient (95% CI) P-value
Age (per year) 100 0.05 0.08 (− 0.22, 0.38) 0.598
Gender (female)b 100 − 0.01 − 0.31 (− 9.43, 8.80) 0.946
BMI (kg/m2) 100 − 0.01 − 0.03 (− 1.01, 0.95) 0.945
Treated hypertension (yes)b 100 0.04 1.75 (− 7.09, 10.59) 0.695
Permanent AF (yes)b 100 − 0.32 − 15.60 (− 24.97, − 6.23) 0.001
Log2CVFmean (%)
a 83 − 0.18 − 3.82 (− 8.45, 0.82) 0.105
Log2CVFmax (%)
a 83 − 0.11 − 2.20 (− 6.42, 2.03) 0.304
Cardiomyocyte CSA  (um2) 83 0.13 0.01 (− 0.01, 0.03) 0.245
Echocardiography E/eʹ 87 − 0.36 − 1.60 (− 2.49, − 0.70) 0.001
PASP (mmHg) 81 − 0.28 − 0.43 (− 0.76, − 0.10) 0.012
Degeneration subtype (Barlow’s)b 91 0.02 0.77 (− 8.18, 9.72) 0.865
LVEF (%) 100 0.23 0.57 (0.09, 1.05) 0.021
GCS (%) 98 − 0.26 − 1.64 (− 2.87, − 0.42) 0.009
GLS (%) 98 − 0.32 − 2.19 (− 3.50, − 0.87) 0.001
LVESVI (ml/m2) 100 − 0.20 − 0.34 (-0.67, − 0.01) 0.045
LVMI (g/m2) 100 0.03 0.05 (− 0.26, 0.36) 0.739
RVEF (%) 100 0.41 0.96 (0.54, 1.39) < 0.001
RV  Ell 100 − 0.20 − 0.84 (− 1.69, 0.01) 0.051
RVESVI (ml/m2) 100 − 0.23 − 0.44 (− 0.83, − 0.06) 0.024
MR volume (ml) 100 − 0.19 − 0.13 (− 0.26, 0.00) 0.057
MR fraction (%) 100 − 0.40 − 0.55 (− 0.80, − 0.30) < 0.001
ECV (%) 98 − 0.22 − 1.37 (− 2.60, − 0.13) 0.030
Native T1 (ms) 100 − 0.07 − 0.06 (− 0.22, 0.10) 0.471
LGE presence (yes)b 99 0.01 0.33 (− 8.42, 9.08) 0.941
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main patterns: thickened endocardium with increased 
fibrosis in biopsies containing sub endocardium; cellular 
hypertrophy and increased fibrosis compared to con-
trols; and a variable degree of fat infiltration. Despite the 
increase in fibrosis compared to control subjects without 
MR, both in asymptomatic and symptomatic patients, 
the extent of fibrosis on myocardial biopsy at the time of 
surgery was not related to LVEF, GLS, diastolic function 
(E/e′; left atrial volume) or MR severity. Biopsy and CMR 
offered complementary information however, because 
patterns of fibrosis proved variable, and CMR-derived 
ECV and LGE were not able to capture the subendo-
cardial changes highlighted on histology. Hence, while 
the extent of fibrosis on myocardial biopsy was related 
to symptoms but was not related to LV function, non-
invasive tissue characterisation with ECV was associated 
with changes in both systolic and diastolic function, and 
measured exercise capacity.
The new finding of significant myocardial fibrosis in 
asymptomatic patients contrasts with early autopsy 
data, which found a significant increase in the size of 
the interstitial space only in those patients with severe 
MR (NYHA Class III–IV) who died early after mitral 
valve replacement from cardiac failure with low cardiac 
output syndrome [4]. Although the study did document 
an increase in size of the interstitial space in less symp-
tomatic patients with severe MR (NYHA Class II–III) 
but who died early after mitral valve replacement from 
causes other than cardiac failure, this was not signifi-
cant compared to autopsy controls. We believe there 
are technical issues and issues of sensitivity that explain 
these differences. Firstly, the retrospective study by Fus-
ter et  al. used hearts collected in 10% formalin over a 
10-year period 1962–1972 and quantified the intersti-
tial space using photographs on which the interstitial 
space was highlighted in white pen, without histological 
characterisation. In contrast, samples in our study were 
stained for fibrosis that was then quantified directly, as 
was the degree of fatty infiltration. Secondly, we suspect 
that ECV may be a more sensitive 3D measure of the 
interstitial space, while acknowledging that the range of 
ECV observed within our surgical cohort (27.3 ± 3.2%) 
was only mildly raised compared to the mean ECV of 
25.9% (95% CI 25.5–26.3%) within a recent pooled analy-
sis of 3872 participants [20]. This low-grade ECV expan-
sion observed within our study may be related to disease 
duration, which is difficult to quantify, but most of our 
patients were under follow-up in valve clinic and were 
referred for early surgery, while LV size, function and 
mass were normal, and with unrestricted exercise capac-
ity on formal testing. This latter pooled analysis also 
highlights the large confidence intervals and significant 
overlap in T1 and ECV values between health and disease 
[20], which reflects the recognised limitations of ECV 
and T1 analyses.
Despite evidence that high native T1, elevated ECV, 
and LGE measure diffuse interstitial and replacement 
fibrosis in other diseases [21–24], we found no correla-
tion between overall  CVFmean and CMR measures of 
fibrosis. There are a number of potential reasons for this. 
Similar to previous reports [7], we noted the incidence 
of LGE to be 34% in our MR cohort, but the most com-
mon location was in the basal inferolateral LV wall and 
associated papillary muscles. Although the inferolateral 
wall was one of the three pre-specified targets to be biop-
sied, the focal nature of the fibrosis means this could have 
been missed. This situation is best exemplified by the 
low sensitivity of myocardial biopsy in the diagnoses of 
cardiac sarcoidosis [25], and mirrors the data for aortic 
valve diseases where some groups have been able to dem-
onstrate a significant correlation between histological 
and CMR quantified fibrosis [24], whilst others have not 
[26]. We report a low ICC for CVF from multiple biopsy 
sites within the same heart; this finding is reminiscent 
of the large (43%) coefficient of variation reported for 
interstitial fibrosis (but only 3% for cardiomyocyte CSA) 
in dilated cardiomyopathy [27]. This may also help to 
explain why ECV—a measure of global myocardial status, 
correlated with CMR measures of biventricular systolic 
function and echo derived E/e, highlighting the poten-
tial value of ECV as a marker of LV remodelling in MR. 
Finally, avoidance of the endocardium during quantifica-
tion of ECV to prevent blood pool contamination may 
also contribute to the discordant results with histology, 
a hypothesis which is supported by our sub-analyses on 
myocardium-only derived CVF. However, ECV in itself 
has limitations, including cross over of ranges between 
health and disease, practical limitations of movement 
with respiration, and further research is needed on 
whether ECV offers incremental prognostic value over 
traditional cardiac biomarkers such as NTproBNP.
Limitations
This study was observational in nature and therefore no 
causation can be inferred. Although pre-specified, inva-
sive myocardial biopsy was not performed in all patients 
with symptomatic and asymptomatic MR who went 
forward to surgery due to technical difficulties. Despite 
this, we provide the largest histologic characterisation 
of patients with severe primary MR. We were unable to 
anatomically match the location of the autopsy sections 
with the location of our histological biopsies. However, 
there is no evidence for significant regional variations in 
CVF quantity in the healthy heart and therefore this limi-
tation should not detract from the significant difference 
in CVF observed between MR patients and controls. 
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Similarly, anatomical matching of the location of biopsy 
collection with the commonly observed location LGE 
in MR is difficult, and is likely to contribute towards the 
lack of association between CVF and LGE quantifica-
tion. Invasive measurement of pulmonary artery pres-
sures was performed at the clinician’s discretion and was 
not a requirement of this study. Although assessment by 
echocardiography was performed, there were cases inevi-
tably without enough tricuspid regurgitation for pulmo-
nary artery systolic pressure to be measured. Finally, the 
narrower range of global fibrosis quantified by ECV may 
have weakened our ability to detect correlations, where a 
broader range always favours the likelihood of obtaining 
significant results. However, studying a group of severe 
MR patients early in their disease process increases the 
clinical relevance of our findings given the trend for ear-
lier surgical assessment of asymptomatic patients.
Conclusions
Histological evidence of diffuse interstitial and replace-
ment myocardial fibrosis, along with concomitant car-
diomyocyte hypertrophy is present in asymptomatic MR, 
in the presence of normal range LV volume and LVEF. 
Fibrosis on biopsy is patchy and highly variable within 
the heart, which may contribute to the lack of correla-
tion with T1 mapping, ECV and LGE. ECV, as a marker 
of global myocardial status, correlated well with multiple 
measures of ventricular function in MR. Further stud-
ies are warranted to investigate whether latent fibrosis 
detected using T1, ECV or LGE offer incremental value 
in predicting post-operative outcome in asymptomatic 
patients with severe primary MR.
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